

Please amend claims 1-8 as follows:

- Am U7
1. (Amended) A method for preventing or treating at least one symptom of hypercalcemic crisis, comprising the step of administering to a patient at least one substance capable of inhibiting the binding between PTHrP and a receptor thereof.
2. (Amended) The method according to claim 1, wherein the substance is an antagonist against a PTHrP receptor.
3. (Amended) The method according to claim 1, wherein the substance is an anti-PTHrP antibody.
- A2 m7
4. (Amended) The method according to claim 1, wherein the substance is at least one of a fragment of an anti-PTHrP antibody or a modified form of the fragment.
5. (Amended) The method according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.
6. (Amended) The method according to claim 5, wherein the humanized antibody is humanized #23-57-137-1 antibody.
- Am U
7. (Amended) The method according to claim 3 or 4, wherein the antibody is a monoclonal antibody.
8. (Amended) The method according to claim 1, wherein the hypercalcemic crisis is hypercalcemic crisis associated with malignant tumor.

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com